4/A: AN2 Therapeutics Officer Paul Eckburg Amends Filing to Clarify Stock Vesting Schedule
SEC Filing (Form 4/A)
Paul Eckburg, Chief Medical Officer of AN2 Therapeutics, amends a previous SEC Form 4 filing to clarify the vesting schedule of restricted stock units.
Summary
- Paul Eckburg, Chief Medical Officer of AN2 Therapeutics, filed an amended SEC Form 4 to correct information regarding the vesting schedule of restricted stock units.
- The amendment clarifies that 30,000 shares were acquired on March 15, 2024, at a price of $0.
- Following the transaction, Eckburg beneficially owns 51,416 shares of common stock.
- The vesting schedule for the restricted stock units is 1/4th of the shares vesting annually over four years from January 1, 2024, subject to continuous service.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing, indicating standard corporate governance practices. The amendment suggests attention to detail and compliance.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in the biopharmaceutical industry.
Stakeholder Impact
- The clarification of the vesting schedule provides transparency to shareholders regarding executive compensation.
Key Dates
| Date | Description |
|---|---|
| 01/01/2024 | Start date for the vesting schedule of the restricted stock units. |
| 03/15/2024 | Date of the transaction where 30,000 shares were acquired. |
| 03/18/2024 | Date of the original Form 4 filing. |
| 03/29/2024 | Date of the amended Form 4/A filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.